2017 Q1 Form 10-Q Financial Statement
#000119312517166004 Filed on May 10, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $3.009M | $0.00 |
| YoY Change | ||
| Cost Of Revenue | $2.548M | $5.168M |
| YoY Change | -50.7% | 172.0% |
| Gross Profit | $461.0K | -$5.168M |
| YoY Change | -108.92% | 172.0% |
| Gross Profit Margin | 15.32% | |
| Selling, General & Admin | $15.39M | $7.351M |
| YoY Change | 109.35% | -29.99% |
| % of Gross Profit | 3338.18% | |
| Research & Development | $3.129M | $5.130M |
| YoY Change | -39.01% | -45.29% |
| % of Gross Profit | 678.74% | |
| Depreciation & Amortization | $400.0K | $600.0K |
| YoY Change | -33.33% | -73.91% |
| % of Gross Profit | 86.77% | |
| Operating Expenses | $18.52M | $20.01M |
| YoY Change | -7.47% | -7.94% |
| Operating Profit | -$19.60M | -$20.01M |
| YoY Change | -2.05% | -7.94% |
| Interest Expense | $1.800M | -$4.900M |
| YoY Change | -136.73% | -52.43% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $3.278M | -$4.860M |
| YoY Change | -167.45% | -443.95% |
| Pretax Income | -$16.32M | -$24.87M |
| YoY Change | -34.37% | -18.87% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$16.32M | -$24.87M |
| YoY Change | -34.37% | -18.87% |
| Net Earnings / Revenue | -542.51% | |
| Basic Earnings Per Share | -$0.17 | -$0.29 |
| Diluted Earnings Per Share | -$0.17 | -$0.29 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 95.74M | 85.77M |
| Diluted Shares Outstanding | 95.74M | 85.77M |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $48.00M | $27.70M |
| YoY Change | 73.29% | -77.07% |
| Cash & Equivalents | $47.98M | $27.65M |
| Short-Term Investments | ||
| Other Short-Term Assets | $4.000M | $16.30M |
| YoY Change | -75.46% | -0.61% |
| Inventory | $3.698M | |
| Prepaid Expenses | ||
| Receivables | $438.0K | $144.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $56.09M | $44.14M |
| YoY Change | 27.07% | -72.11% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $28.48M | $48.03M |
| YoY Change | -40.7% | -75.17% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $609.0K | $1.096M |
| YoY Change | -44.43% | -45.93% |
| Total Long-Term Assets | $29.09M | $49.13M |
| YoY Change | -40.79% | -75.65% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $56.09M | $44.14M |
| Total Long-Term Assets | $29.09M | $49.13M |
| Total Assets | $85.19M | $93.27M |
| YoY Change | -8.67% | -74.09% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.519M | $582.0K |
| YoY Change | 161.0% | -82.37% |
| Accrued Expenses | $10.66M | $8.077M |
| YoY Change | 31.94% | -34.76% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $71.80M | $75.00M |
| YoY Change | -4.27% | 2.18% |
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $93.05M | $249.2M |
| YoY Change | -62.66% | -34.55% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $77.20M | $146.0M |
| YoY Change | -47.12% | 194.95% |
| Other Long-Term Liabilities | $113.7M | $15.95M |
| YoY Change | 613.03% | -40.45% |
| Total Long-Term Liabilities | $190.9M | $15.95M |
| YoY Change | 1097.17% | -40.45% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $93.05M | $249.2M |
| Total Long-Term Liabilities | $190.9M | $15.95M |
| Total Liabilities | $283.9M | $466.7M |
| YoY Change | -39.17% | 2.12% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$2.754B | -$2.888B |
| YoY Change | -4.65% | 14.36% |
| Common Stock | $2.555B | $2.515B |
| YoY Change | 1.61% | 3.55% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$198.7M | -$373.5M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $85.19M | $93.27M |
| YoY Change | -8.67% | -74.09% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$16.32M | -$24.87M |
| YoY Change | -34.37% | -18.87% |
| Depreciation, Depletion And Amortization | $400.0K | $600.0K |
| YoY Change | -33.33% | -73.91% |
| Cash From Operating Activities | $8.510M | -$30.76M |
| YoY Change | -127.67% | -1118.54% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $1.144M |
| YoY Change | -100.0% | -72.78% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $16.65M | $20.00K |
| YoY Change | 83150.0% | |
| Cash From Investing Activities | $16.65M | -$1.130M |
| YoY Change | -1573.45% | -73.1% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -80.00K | 460.0K |
| YoY Change | -117.39% | -61.34% |
| NET CHANGE | ||
| Cash From Operating Activities | 8.510M | -30.76M |
| Cash From Investing Activities | 16.65M | -1.130M |
| Cash From Financing Activities | -80.00K | 460.0K |
| Net Change In Cash | 25.08M | -31.43M |
| YoY Change | -179.8% | -314400.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $8.510M | -$30.76M |
| Capital Expenditures | $0.00 | $1.144M |
| Free Cash Flow | $8.510M | -$31.90M |
| YoY Change | -126.67% | 2596.87% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
101006255 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
140000000 | shares |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
27653000 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
700000000 | shares |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
140000000 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
95776297 | shares |
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
95776297 | shares |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2017Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-2753889000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
283910000 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
85185000 | |
| CY2017Q1 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
117600000 | |
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3900000 | |
| CY2017Q1 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
752000 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1844000 | |
| CY2017Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-24000 | |
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1519000 | |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-198725000 | |
| CY2017Q1 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
8900000 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
56094000 | |
| CY2017Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
3296000 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
28482000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
47978000 | |
| CY2017Q1 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
49521000 | |
| CY2017Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
221000 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
958000 | |
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2554230000 | |
| CY2017Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
100020000 | |
| CY2017Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1505000 | |
| CY2017Q1 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
772000 | |
| CY2017Q1 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
11600000 | |
| CY2017Q1 | us-gaap |
Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
|
15500000 | |
| CY2017Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
20000000 | |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
|
15500000 | |
| CY2017Q1 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
71795000 | |
| CY2017Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
799000 | |
| CY2017Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
35000000 | |
| CY2017Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
20000000 | |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
93049000 | |
| CY2017Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
27642000 | |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
10657000 | |
| CY2017Q1 | us-gaap |
Inventory Net
InventoryNet
|
3698000 | |
| CY2017Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
438000 | |
| CY2017Q1 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
47400000 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
128502000 | |
| CY2017Q1 | us-gaap |
Assets
Assets
|
85185000 | |
| CY2017Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
402000 | |
| CY2017Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
609000 | |
| CY2017Q1 | us-gaap |
Other Deferred Costs Net
OtherDeferredCostsNet
|
472000 | |
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3508000 | |
| CY2017Q1 | mnkd |
Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
|
821000 | |
| CY2017Q1 | mnkd |
Purchase Obligation Noncurrent
PurchaseObligationNoncurrent
|
95062000 | |
| CY2017Q1 | mnkd |
Accrued Interest Of Related Party Debt
AccruedInterestOfRelatedPartyDebt
|
10000000 | |
| CY2017Q1 | mnkd |
Purchase Obligation Current
PurchaseObligationCurrent
|
6984000 | |
| CY2017Q1 | mnkd |
Cash Discount Percent
CashDiscountPercent
|
0.02 | pure |
| CY2017Q1 | mnkd |
Customer Discounts And Allowances
CustomerDiscountsAndAllowances
|
996000 | |
| CY2017Q1 | mnkd |
Purchase Obligation Due In Remainder Of Fiscal Year
PurchaseObligationDueInRemainderOfFiscalYear
|
2700000 | |
| CY2017Q1 | mnkd |
Deferred Collaborative Credit Current
DeferredCollaborativeCreditCurrent
|
250000 | |
| CY2017Q1 | mnkd |
Purchase Obligation Due In Sixth Year
PurchaseObligationDueInSixthYear
|
19400000 | |
| CY2017Q1 | mnkd |
Accrued Interest Noncurrent
AccruedInterestNoncurrent
|
9995000 | |
| CY2017Q1 | mnkd |
Milestone Rights Liability And Other Liabilities Noncurrent
MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent
|
7202000 | |
| CY2017Q1 | mnkd |
Purchase Obligation Due In Seventh Year
PurchaseObligationDueInSeventhYear
|
19400000 | |
| CY2017Q1 | mnkd |
Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
|
0.92 | pure |
| CY2017Q1 | mnkd |
Current Portion Of Milestone Right Liability
CurrentPortionOfMilestoneRightLiability
|
1643000 | |
| CY2017Q1 | mnkd |
Deferred Collaborative Credit Noncurrent
DeferredCollaborativeCreditNoncurrent
|
687000 | |
| CY2017Q1 | mnkd |
Number Of Customers Accounted For Gross Accounts Receivable
NumberOfCustomersAccountedForGrossAccountsReceivable
|
3 | Distributor |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
59074000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
140000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
95680831 | shares |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
95680831 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-2737565000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
290656000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
107063000 | |
| CY2016Q4 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
123200000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3814000 | |
| CY2016Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
7381000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
3419000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-24000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3263000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-183593000 | |
| CY2016Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
49521000 | |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
619000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
957000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2553039000 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
99575000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
875000 | |
| CY2016Q4 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
1376000 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Other Long Term Debt Current
OtherLongTermDebtCurrent
|
71339000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
355000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
92051000 | |
| CY2016Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
27635000 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7937000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
77488000 | |
| CY2016Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
2120000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
28927000 | |
| CY2016Q4 | us-gaap |
Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
|
16730000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22895000 | |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
2331000 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
302000 | |
| CY2016Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
30557000 | |
| CY2016Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
20500000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
128502000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
107063000 | |
| CY2016Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
211000 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
648000 | |
| CY2016Q4 | us-gaap |
Other Deferred Costs Net
OtherDeferredCostsNet
|
309000 | |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4364000 | |
| CY2016Q4 | mnkd |
Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
|
144000 | |
| CY2016Q4 | mnkd |
Purchase Obligation Noncurrent
PurchaseObligationNoncurrent
|
95942000 | |
| CY2016Q4 | mnkd |
Accrued Interest Of Related Party Debt
AccruedInterestOfRelatedPartyDebt
|
9300000 | |
| CY2016Q4 | mnkd |
Purchase Obligation Current
PurchaseObligationCurrent
|
5093000 | |
| CY2016Q4 | mnkd |
Customer Discounts And Allowances
CustomerDiscountsAndAllowances
|
754000 | |
| CY2016Q4 | mnkd |
Deferred Collaborative Credit Current
DeferredCollaborativeCreditCurrent
|
1000000 | |
| CY2016Q4 | mnkd |
Accrued Interest Noncurrent
AccruedInterestNoncurrent
|
9281000 | |
| CY2016Q4 | mnkd |
Milestone Rights Liability And Other Liabilities Noncurrent
MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent
|
8845000 | |
| CY2016Q4 | mnkd |
Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
|
0.95 | pure |
| CY2016Q4 | mnkd |
Number Of Customers Accounted For Gross Accounts Receivable
NumberOfCustomersAccountedForGrossAccountsReceivable
|
3 | Distributor |
| CY2017Q1 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.2 | pure |
| CY2016 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
11600000 | |
| CY2016 | mnkd |
Deferred Revenue From Sale Of Raw Insulin
DeferredRevenueFromSaleOfRawInsulin
|
1800000 | |
| CY2016 | mnkd |
Loss On Purchase Commitments Number Of Contracts Recognized
LossOnPurchaseCommitmentsNumberOfContractsRecognized
|
0 | pure |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17205570 | shares |
| CY2017Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2017Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2017Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000899460 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
8507000 | |
| CY2017Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Reclassifications</i> — Certain amounts from previous periods have been reclassified to conform to the 2017 presentation. Specifically, on the condensed consolidated statements of operations, product manufacturing has been renamed to costs of goods sold. The Company also reclassified (gain) loss on foreign currency translation from the previously reported classification of product manufacturing to loss on foreign currency translation in the accompanying condensed consolidated statements of operations. In addition, on the statements of cash flows, the Company reclassified interest expense on note payable to principal stockholder from other liabilities to conform to the 2017 presentation.</p> </div> | |
| CY2017Q1 | us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Revenue Recognition – Net Revenue – Collaborations –</i> The Company enters into collaborations under which the Company must perform certain obligations and receives periodic payments. The Company evaluates the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 7 — Collaboration Arrangements.</p> </div> | |
| CY2017Q1 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
The Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. | |
| CY2017Q1 | dei |
Trading Symbol
TradingSymbol
|
MNKD | |
| CY2017Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.86 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
|
77680 | shares |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
95744000 | shares |
| CY2017Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | |
| CY2017Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2017Q1 | us-gaap |
Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Deferred Costs from Commercial Product Sales</i> — Deferred costs from commercial product sales represents the cost of product (including labor, overhead and shipping costs to the third party logistics provider) shipped to wholesale distributors, but not dispensed by retail pharmacies to patients. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiry, deferred costs of commercial product sales is reduced and cost of goods sold is increased for the cost of such inventory.</p> </div> | |
| CY2017Q1 | us-gaap |
Revenue Recognition Discounts
RevenueRecognitionDiscounts
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> <i>Prompt Pay Discounts –</i> The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable and deferred revenue by the prompt pay discount amount (at the time of shipment to the wholesale distributor). The Company recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> <i>Rebates and Chargebacks –</i> The Company participates in federal and state government-managed Medicare and Medicaid programs and, as such, is required to provide rebates under these programs. The Company continues to pursue participation in certain other qualifying federal and state government programs whereby discounts and rebates are provided to participating entities. Rebates provided through these other qualifying programs are included in the Medicaid and Medicare rebate accrual. Chargebacks are discounts that occur when contracted customers purchase directly from an intermediary wholesale purchaser. Contracted customers, which currently consist primarily of Federal government entities purchasing off the Federal Supply Schedule, generally purchase the product at its contracted price, plus a mark-up from the wholesaler. The wholesaler, in-turn, charges back to the Company the difference between the price initially paid by the wholesaler and the contracted price paid to the wholesaler by the customer.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rates. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates may be paid can be up to approximately six to nine months. As such, continuous monitoring of these estimates will be performed on a periodic basis, and if necessary, adjusted to reflect new facts and circumstances. Rebates and chargebacks are recognized as a reduction of gross revenue in the period the related revenue is recognized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 8%; MARGIN-TOP: 6pt"> <i>Other Rebates and Discounts –</i> The Company has entered into agreements with certain third-party payors and with pharmacy benefit managers that act as an intermediary with certain third-party payors in the fulfillment of prescriptions. Under these agreements, the Company has agreed to provide certain contracted discounts to ease access to reimbursement for Afrezza patients including, but not limited to, the removal of prior authorization or step edit requirements or modifying the reimbursement tier under the payor’s formulary. The Company accounts for these charges by establishing an accrual based on the contracted discount rates and, with input received from management, estimated participation rates.</p> </div> | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
908000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.17 | |
| CY2017Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
MANNKIND CORP | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y9M18D | |
| CY2017Q1 | us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Revenue Recognition – Net Revenue – Commercial Product Sales –</i> Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (ICS) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”. The Company provides the right of return to its wholesale distributors and, through them, to its retail pharmacy customers for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in <i>Gross-to-Net Adjustments</i> below. The Company recognizes revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> For the three months ended March 31, 2017, net revenue from commercial product sales consisted of $1.2 million of net sales of Afrezza dispensed to patients. As of March 31, 2017 and December 31, 2016, the ending balances for deferred revenue were $1.8 million and $3.4 million, on its condensed consolidated balance sheets, of which $1.8 million and $1.6 million (net of estimated gross-to-net adjustments), respectively, represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference, as of December 31, 2016, represented deferred revenue from bulk insulin sales, which is described more fully under the heading <i>Revenue Recognition – Revenue – Bulk Insulin Sales</i> below. For the three months ended March 31, 2017, shipments to three wholesale distributors represented 93% of total shipments.</p> </div> | |
| CY2017Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
3009000 | |
| CY2017Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
1196000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19602000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16324000 | |
| CY2017Q1 | us-gaap |
Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
|
93000000 | |
| CY2017Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2550000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-39000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1367000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
136000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16324000 | |
| CY2017Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
75000 | |
| CY2017Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
55000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
|
-30557000 | |
| CY2017Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
14000 | |
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3278000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-856000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-16324000 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-1545000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1300000 | |
| CY2017Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
400000 | |
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
|
-63000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1077000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1665000 | |
| CY2017Q1 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
714000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
16651000 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
16651000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1267000 | |
| CY2017Q1 | mnkd |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
6629000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1575000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
3129000 | |
| CY2017Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
15389000 | |
| CY2017Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
22611000 | |
| CY2017Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
2706000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-75000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
25083000 | |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2548000 | |
| CY2017Q1 | us-gaap |
Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
|
604000 | |
| CY2017Q1 | mnkd |
Longterm Purchase Commitment Renewal Time Period
LongtermPurchaseCommitmentRenewalTimePeriod
|
P2Y | |
| CY2017Q1 | mnkd |
Number Of Wholesale Distributors
NumberOfWholesaleDistributors
|
3 | Distributor |
| CY2017Q1 | mnkd |
Number Of Equal Tranches
NumberOfEqualTranches
|
4 | Tranche |
| CY2017Q1 | mnkd |
Long Term Purchase Commitment Expiration Date
LongTermPurchaseCommitmentExpirationDate
|
2023-12-31 | |
| CY2017Q1 | mnkd |
Interest On Note Payable To Principal Stockholder
InterestOnNotePayableToPrincipalStockholder
|
714000 | |
| CY2017Q1 | mnkd |
Minimum Bid Price Requirement
MinimumBidPriceRequirement
|
1.00 | |
| CY2017Q1 | mnkd |
Net Revenue From Collaboration
NetRevenueFromCollaboration
|
63000 | |
| CY2017Q1 | mnkd |
Increase Decrease In Other Deferred Charges
IncreaseDecreaseInOtherDeferredCharges
|
163000 | |
| CY2016Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
3000 | |
| CY2017Q1 | mnkd |
Nasdaq Listing Minimum Bid Price Requirement Description
NasdaqListingMinimumBidPriceRequirementDescription
|
On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that in the previous 30 consecutive business days, the bid price for the common stock closed below the minimum of $1.00 per share required for continued inclusion on the NASDAQ Global Market. | |
| CY2017Q1 | mnkd |
Fair Value Of Liability Percentage Increase
FairValueOfLiabilityPercentageIncrease
|
0.08 | pure |
| CY2017Q1 | mnkd |
Fair Value Of Liability Percentage Decrease
FairValueOfLiabilityPercentageDecrease
|
0.07 | pure |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-24872000 | |
| CY2017Q1 | mnkd |
Increase Decrease In Purchase Commitment Loss
IncreaseDecreaseInPurchaseCommitmentLoss
|
-534000 | |
| CY2017Q1 | mnkd |
Deferred Revenue From Sale Of Raw Insulin
DeferredRevenueFromSaleOfRawInsulin
|
0 | |
| CY2017Q1 | mnkd |
Net Revenue From Bulk Insulin
NetRevenueFromBulkInsulin
|
1750000 | |
| CY2017Q1 | mnkd |
Loss On Purchase Commitments Number Of Contracts Recognized
LossOnPurchaseCommitmentsNumberOfContractsRecognized
|
0 | pure |
| CY2017Q1 | mnkd |
Percentage Of Product Shipments To Wholesale Distributors
PercentageOfProductShipmentsToWholesaleDistributors
|
0.93 | pure |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6456117 | shares |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-30758000 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
85772000 | shares |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.29 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1144000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
1000 | |
| CY2016Q1 | us-gaap |
Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
|
558000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20013000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-24873000 | |
| CY2016Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2713000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
86000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
121000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
15000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
67000 | |
| CY2016Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-696000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4860000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1211000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-24873000 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-2364000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1300000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
600000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
|
177000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
488000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-14799000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1127000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
17000 | |
| CY2016Q1 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
721000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1273000 | |
| CY2016Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1023000 | |
| CY2016Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
1168000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
5130000 | |
| CY2016Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
7351000 | |
| CY2016Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
20013000 | |
| CY2016Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4221000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
464000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-31421000 | |
| CY2016Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
5168000 | |
| CY2016Q1 | mnkd |
Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
|
467000 | |
| CY2016Q1 | mnkd |
Interest On Note Payable To Principal Stockholder
InterestOnNotePayableToPrincipalStockholder
|
721000 |
